Abstract:AIM: To determine the relationship between CD11c expression level and prognosis in patients with gastric cancer (GC).METHODS: This retrospective survival study was performed from July 31, 2008 to June 30, 2014. Our study inclusion criteria included all the patients with GC who underwent surgical resection between January 1998 and December 2009 in the Third Affiliated Hospital of Soochow University. CD11c expression levels in 140 patients with GC at different UICC stages were evaluated using immunohistochemistry, and GC tissues from 16 cases were further verified by qRT-PCR. The chi(2) test was used to compare the patient- and disease-related factors between the low CD11c expression group and the high expression group. Univariate probabilities of overall survival (OS) and disease-free survival (DFS) were assessed using the Kaplan-Meier method. The log rank test was used to compare survival curves. Different multivariate COX models were used to estimate the association between CD11c expression and both death and recurrence risk in GC patients.RESULTS: The average CD11c expression level was 5.1 +/- 1.8/high power field (HPF) in 10 gastritis samples, 4.5 +/- 2.3/HPF in 10 gastric polyp samples and 9.7 +/- 6.3/ HPF in 140 gastric cancer samples, respectively. The CD11c expression level was significantly decreased from UICC stage. to stage. (stage.: 16.0 +/- 7.4, stage.: 10.4 +/- 5.5, stage.: 9.4 +/- 6.1, stage.: 5.3 +/- 3.2, P < 0.001). Patients in the high CD11c expression group had a greater 3- and 5-year OS probability and longer median survival time compared with the low CD11c expression group, (67.7% vs 39.2%; 51.4% vs 29.0%; 67.0 mo vs 28.0 mo; chi(2) = 6.80, P = 0.009), and had a greater 3-and 5-year DFS probability and longer median DFS time (63.7% vs 24.0%; 49.1% vs 11.9%; 64.0 mo vs 18.0 mo;chi(2) = 15.39, P < 0.001). Patients with high CD11c high expression had a reduced risk of death (HR = 0.56, 95% CI: 0.33-0.98, P < 0.05) and relapse (HR = 0.39, 95% CI: 0.23-0.67, P < 0.01) compared with patients with low CD11c expression after adjustment of potential confounders, with the exception of tumor size. However, the protective effect related to death (HR = 0.90, 95% CI: 0.49-1.67, P = 0.749) and relapse (HR = 0.65, 95% CI: 0.36-1.19, P = 0.160) disappeared when tumor size was incorporated into the model.CONCLUSION: High expression of CD11c decreased the risk of death and relapse, and may be regarded as an alternative indicator of favorable prognosis in patients with GC.

Low Expression of CD80 Predicts for Poor Prognosis in Patients with Gastric Adenocarcinoma.

Clinicopathological and related gene analysis in gastric adenocarcinoma and their correlation with prognosis

Dystroglycan is Associated with Tumor Progression and Patient Survival in Gastric Cancer

Low Expression of CDK10 Correlates with Adverse Prognosis in Gastric Carcinoma

High Expression of CD11c Indicates Favorable Prognosis in Patients with Gastric Cancer

CD40 Signal Expression in Gastric Cancer Tissue and Its Correlation with Prognosis of Gastric Cancer Patients

Significance of CD80 as a Prognostic and Immunotherapeutic Biomarker in Lung Adenocarcinoma

[Expression of CD40 in human gastric cancer tissue and its prognostic correlation].

Upregulation of Programmed Death Ligand 1 and Epidermal Growth Factor Receptor is Associated with Poor Prognosis in Gastric Cancer

Expression and Clinical Significance of CD8 + T Cells in Gastric Carcinoma Tissues

PD-L 1 Expression and CD 8 + T Cell Infiltration Predict a Favorable Prognosis in Advanced Gastric Cancer

High CDX2 Expression Predicts a Favorable Prognosis in Patients with Early-Stage Gastric Adenocarcinoma

Tumor-infiltrating CD8+ T cells combined with tumor-associated CD68+ macrophages predict postoperative prognosis and adjuvant chemotherapy benefit in resected gastric cancer

Expression and Significance of CD28, CTLA-4, CD80 and CD86 in Gastric Cancer

Expression Of Cd40 And Cd40l In Gastric Cancer Tissue And Its Clinical Significance

Expression of P53, EGFR, HER-2, VEGF in Gastric Carcinoma and Its Relation with the Prognosis of Gastric Carcinoma Patients

Identification and Validation of an Immunogenic Subtype of Gastric Cancer with Abundant Intratumoural CD103+CD8+ T Cells Conferring Favourable Prognosis.

High Expression of EGFR Predicts Poor Survival in Patients with Resected T3 Stage Gastric Adenocarcinoma and Promotes Cancer Cell Survival

Upregulation Of C-X-C Chemokine Receptor Type 1 Expression Is Associated With Late-Stage Gastric Adenocarcinoma

Ectopic Expression of B and T Lymphocyte Attenuator in Gastric Cancer: A Potential Independent Prognostic Factor in Patients with Gastric Cancer

Intratumoral Foxp3+RORγt+ T Cell Infiltration Determines Poor Prognosis and Immunoevasive Contexture in Gastric Cancer Patients